Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

429 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Ascaso JF, Fernández-Cruz A, González Santos P, Hernández Mijares A, Mangas Rojas A, Millán J, Felipe Pallardo L, Pedro-Botet J, Pérez-Jiménez F, Pía G, Pintó X, Plaza I, Rubiés-Prat J; HDL Forum. Ascaso JF, et al. Among authors: pinto x. Am J Cardiovasc Drugs. 2004;4(5):299-314. doi: 10.2165/00129784-200404050-00003. Am J Cardiovasc Drugs. 2004. PMID: 15449972 Review.
[Diagnosis of metabolic syndrome. Adaptation of diagnostic criteria in our setting. Recommendations of the HDL forum].
Ascaso JF, González-Santos P, Hernández Mijares A, Mangas Rojas A, Masana Marín L, Millán Núñez-Cortés J, Pallardo LF, Pedro-Botet J, Pérez-Jiménez F, Pintó X, Plaza I, Rubiés-Prat J, Zúñiga M; FORO-HDL. Ascaso JF, et al. Among authors: pinto x. Rev Clin Esp. 2006 Dec;206(11):576-82. doi: 10.1157/13096308. Rev Clin Esp. 2006. PMID: 17178079 Spanish. No abstract available.
Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA, Cachofeiro V, Masana L, Suarez C, Pinilla B, Plana N, Trias F, Moreno MA, Gambus G, Lahera V, Pintó X. Alvarez-Sala LA, et al. Among authors: pinto x. Clin Ther. 2008 Jan;30(1):84-97. doi: 10.1016/j.linthera.2008.01.013. Clin Ther. 2008. PMID: 18343245 Clinical Trial.
[Emerging risk factors related to residual risk].
Millán J, Pedro-Botet J, Pintó X; en nombre de la Organización R3i (Residual Risk Reduction initiative) de España. Millán J, et al. Among authors: pinto x. Med Clin (Barc). 2011 Jun 11;137(2):92-3. doi: 10.1016/j.medcli.2010.09.025. Epub 2010 Dec 8. Med Clin (Barc). 2011. PMID: 21145077 Spanish. No abstract available.
[Residual lipid profile in recurrent ischemic cardiopathy].
Millán J, Pedro-Botet J, Muñoz A, Corbella E, Mangas A, Zúñiga M, Hernández-Mijares A, Pintó X. Millán J, et al. Among authors: pinto x. Med Clin (Barc). 2012 Mar 17;138(6):238-41. doi: 10.1016/j.medcli.2011.01.010. Epub 2011 Mar 22. Med Clin (Barc). 2012. PMID: 21429535 Spanish.
429 results